



A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study

Ieva Saulite

type of project	clinical studies
status	ongoing - recruiting phase
start of project	2022
end of project	2024
responsible person	Ieva Saulite